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Introduction {#rcr2201-sec-0001}
============

Pulmonary alveolar proteinosis (PAP) was first described in 1958 by Rosen et al. as an infrequently seen disorder in which an amorphous, insoluble, lipoproteinaceous material tends to accumulate in the alveolar spaces, causing impairment of gas exchange [1](#rcr2201-bib-0001){ref-type="ref"}. Although the first reported cases were felt to be idiopathic, there have been subsequent reports suggesting that PAP could be a secondary phenomenon, resulting from exposure to silica, silicates, aluminium, fibreglass particles, and infectious agents such as *Pneumocystis jirovecii*, Nocardia, and mycobacteria, as well as associated with haematological malignancies. We report the case of a man who developed PAP syndrome following a 2‐year exposure to silica dust and subsequently reviewed the world literature where 363 cases were found.

Case Report {#rcr2201-sec-0002}
===========

A 52‐year‐old white male with a 60 pack‐year history of cigarette smoking presented with progressive dyspnoea on exertion for 18 months. He had worked in an environment where other workers were placing tiles and cutting floors, without wearing a mask. He had a long‐standing cough with whitish sputum production, but denied fever, chills, weight loss, night sweats, and other symptoms.

Physical examination revealed a mildly dyspnoeic patient with normal vital signs; heart auscultation was normal; bibasilar fine late inspiratory rales involving half the way up in both lung fields were heard. Laboratory analyses showed haemoglobin (Hb) 17 g/dL, white blood cells (WBC) 8.700/mm^3^, and routine chemistry results including liver function tests were normal. Arterial blood gases: PaO~2~, 76 mmHg; PaCO~2~, 35 mmHg; and pH, 7.44. Pulmonary function tests revealed FVC: 4.69 L (89% of predicted), FEV1 3.73 L (92%), FEV1/FVC 80%, TLC 5.76 L (78%), and DLCO 16.8 mL/min/mmHg (54%). Chest radiograph revealed bilateral alveolar infiltrates (Fig. [1](#rcr2201-fig-0001){ref-type="fig"}). Fiberoptic bronchoscopy failed to reveal any endobronchial lesion but yielded biopsies disclosing alveoli filled with periodic acid of Schiff (PAS)‐positive lipoproteinaceous material and refringent particles compatible with silicates, and negative cultures (Fig. [2](#rcr2201-fig-0002){ref-type="fig"}A, B). A therapeutic whole lung lavage (WLL) was carried out, resulting is an immediate improvement in symptoms as well as in gas exchange.

![(A) Chest X‐ray and (B) computerized tomography of the chest disclosing bilateral alveolar infiltrates in butterfly distribution, sparing the costophrenic angles characteristic of pulmonary alveolar proteinosis.](RCR2-4-0-g001){#rcr2201-fig-0001}

![(A) High power view of an H&E stain of lung biopsy revealing alveoli filled with periodic acid--Schiff‐positive proteinaceous material. (B) Polarized light microscopy showing birefringent particles compatible with silicate deposits in the pulmonary interstitium.](RCR2-4-0-g002){#rcr2201-fig-0002}

Discussion {#rcr2201-sec-0003}
==========

This case supports the hypothesis that PAP should not be considered idiopathic until we exclude all the occupational aetiologies. Indeed, the relationship between the occupational exposure and the pulmonary reaction is evident in this patient. The intra‐alveolar accumulation of PAS‐positive material designated as PAP, has been reported to occur occasionally in workers exposed to high concentrations of fine particulate silica. This condition was first reported in 1969 by Buechner et al. [2](#rcr2201-bib-0002){ref-type="ref"}.

When humans and animals inhale high concentrations of silica over a short period of time, the lining cells of the airways are damaged and a lipid‐rich protein exudate accumulates, obliterating the air spaces. These events are followed by type II pneumocyte hypertrophy and hyperplasia, and increased production of phospholipid. In an experimental model, production of dipalmitoyl lecithin increased threefold, while the elimination of the material decreased. Under these circumstances, phagocytosis and the removal of particles were impaired [3](#rcr2201-bib-0003){ref-type="ref"}, [4](#rcr2201-bib-0004){ref-type="ref"}. Rats exposed to high concentration of quartz dust developed alveolar proteinosis with some foci of desquamative pneumonitis and there was a great deal of aggregated silica in that proteinaceous material [5](#rcr2201-bib-0005){ref-type="ref"}. Since 1980 there have been several cases published in the English literature of PAP with silicosis and we think that some cases could have been assumed to be idiopathic PAP [6](#rcr2201-bib-0006){ref-type="ref"}. This case report of silica dust exposure coexisting with PAP, and the experimental finding that inhaled fine silica dust in animals can cause a similar disease [7](#rcr2201-bib-0007){ref-type="ref"}, support the hypothesis that inhaled dust is responsible for the development of PAP, which may not be just a rare idiopathic disease entity, but perhaps a mere, somewhat uncommon pulmonary reaction to a noxious agent. Abraham and McEven, using scanning electron microscopy, demonstrated the presence of inorganic particulates in histological specimens from patients previously diagnosed with PAP [8](#rcr2201-bib-0008){ref-type="ref"}, and they also found that the count of birefringent particles was significantly higher in patients with PAP than in control history and accumulation of inorganic particles in the gas spaces of the lungs. Therefore, it is possible that PAP has multiple causes and that inhaled dusts is one of them.

A literature review was done using Medline. Three hundred and sixty‐three cases were obtained in 36 manuscripts. The chart was arranged chronologically and contained the number of cases per study, the average age in each study, the type of PAP, the way the diagnosis was made, the treatment given, and the survival.

Table [1](#rcr2201-tbl-0001){ref-type="table-wrap"} shows the compilation of 363 chronologically arranged cases worldwide from 1988 to 2014. The age at the diagnosis varied from 1 to 79 years. PAP was classified into *three* groups regarding the aetiology: autoimmune or idiopathic (293 cases of 352 classifiable cases, which represents 83% of the cases), secondary (56 of the 352, which stands for 16% of the classifiable cases), and congenital (only 3 cases reported as such, which comprise 1% of the total). Twelve cases of 363 were not classifiable. PAP was diagnosed on the basis of bronchoalveolar lavage (BAL), transbronchial lung biopsy (TBLB), or open lung biopsy (OLB). Until year 2006, WLL was the only treatment for PAP and the survival was almost 100%. In 2006, oncology researchers discovered serendipitously that knockout mice deprived of granulocyte macrophage--colony stimulating factor (GM‐CSF) gene or receptor developed full blown PAP, which was ameliorated by the administration of GM‐CSF. Thereafter it was conceptualized that GM‐CSF plays an important role in the homeostasis of surfactant production in the alveolar milieu, and then the usefulness of administering GM‐CSF to improve this condition was readily acknowledged. Subsequently, a dual therapy consistent in administration of GM‐CSF and WLL was established.

###### 

Pulmonary alveolar proteinosis world literature review.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference no.                                              Year   N     Ave. age   Autoimmune or idiopathic   Secondary   Congenital   Contrib. factors     Diagnostic method   Treatment           Survival %
  ---------------------------------------------------------- ------ ----- ---------- -------------------------- ----------- ------------ -------------------- ------------------- ------------------- ------------
  Bracci [9](#rcr2201-bib-0009){ref-type="ref"}              1988   1     49                                    1                                             OLB                 BAL                 100

  Lopez [10](#rcr2201-bib-0010){ref-type="ref"}              1991   2     37         2                                                                        OLB                 SR                  100

  Chaudhuri [11](#rcr2201-bib-0011){ref-type="ref"}          1996   1     26                                    1                        TB                   BAL/OLB             Anti‐TB treatment   100

  Kim [12](#rcr2201-bib-0012){ref-type="ref"}                1999   12                                                                                        TBLB                9 WLL\              75
                                                                                                                                                                                  3 Untreated         

  Kokturk [13](#rcr2201-bib-0013){ref-type="ref"}            2000   1     37         1                                                                        TBB/BAL             WLL                 100

  Wali [14](#rcr2201-bib-0014){ref-type="ref"}               2000   1     29         1                                                                        TBB                 WLL                 100

  Barraclough [15](#rcr2201-bib-0015){ref-type="ref"}        2001   1     34                                    1                                             TBB                 GM‐CSF              100

  Beccaria [16](#rcr2201-bib-0016){ref-type="ref"}           2004   21               21                                                                       4 TBB\              WLL                 100
                                                                                                                                                              10 OLB                                  

  Kattan [17](#rcr2201-bib-0017){ref-type="ref"}             2004   1                                                       1                                                     WLL                 

  ker [18](#rcr2201-bib-0018){ref-type="ref"}                2004   1     51                                    1                                             TBB                 WLL                 100

  Kotov [19](#rcr2201-bib-0019){ref-type="ref"}              2006   1     25                                    1                        PJP                  BAL                 BAL                 100

  Indira [20](#rcr2201-bib-0020){ref-type="ref"}             2006   1     53                                                             DM                   OLB                 WLL                 100

  Thomson [21](#rcr2201-bib-0021){ref-type="ref"}            2006   4     27                                    4                                             OLB                 1 SR\               100
                                                                                                                                                                                  3 WLL               

  Tazawa [22](#rcr2201-bib-0022){ref-type="ref"}             2006   35               35                                                  Autoimmune                               25 GM‐CSF           100

  Froudarakis [23](#rcr2201-bib-0023){ref-type="ref"}        2006   1     13         1                                                                        BAL                 WLL                 100

  Wylam [24](#rcr2201-bib-0024){ref-type="ref"}              2006   12    43         12                                                                                           11 GM‐CSF           93

  Ceruti [25](#rcr2201-bib-0025){ref-type="ref"}             2007   1     10                                    1                        LPI                  BAL                 WLL                 100

  Borie [26](#rcr2201-bib-0026){ref-type="ref"}              2009   1     41         1                                                                        TBB                 Rituximab           100

  Ryushi [27](#rcr2201-bib-0027){ref-type="ref"}             2010   50               50                                                                                           35 GM‐CSF           

  Hodges [28](#rcr2201-bib-0028){ref-type="ref"}             2010   1     1                                                 1            Hepatosplenomegaly                       BAL                 100

  Byun [29](#rcr2201-bib-0029){ref-type="ref"}               2010   38               38                                                                       TBB/BAL             WLL                 97

  Ahmed [30](#rcr2201-bib-0030){ref-type="ref"}              2010   8     2          8                                                                        OLB                 WLL/GM‐CSF          25

  Tekgul ^\[^ [31](#rcr2201-bib-0031){ref-type="ref"} ^\]^   2011   1     46                                    1                        TB                   TBB                 Anti‐TB treatment   100

  Moreland [32](#rcr2201-bib-0032){ref-type="ref"}           2011   1     59         1                                                   Exposure to cotton   TBB                 WLL                 100

  Yaqub [33](#rcr2201-bib-0033){ref-type="ref"}              2011   39               39                                                                       BAL                 WLL/Mycophenolate   100

  Bonella [34](#rcr2201-bib-0034){ref-type="ref"}            2011   70               64                         6                        CML                  BAL‐TBB             WLL                 

  Tejwani [35](#rcr2201-bib-0035){ref-type="ref"}            2011   1                                           1                        HIV                  TBB                 WLL                 100

  Canellas [36](#rcr2201-bib-0036){ref-type="ref"}           2012   1     21         1                                                                        TBB                 SR                  100

  Khan [37](#rcr2201-bib-0037){ref-type="ref"}               2012   5     37         4                          1                                             4 OLB\              2 WLL/GM‐CSF\       100
                                                                                                                                                              1 TBB               1 TMP/SMX\          
                                                                                                                                                                                  1 GM‐CSF            

  Shende [38](#rcr2201-bib-0038){ref-type="ref"}             2013   1     58         1                                                   HTN, old TB                              WLL/GM‐CSF          100

  Hammami [39](#rcr2201-bib-0039){ref-type="ref"}            2013   1     1                                                 1                                 BAL                 WLL                 0

  Main [40](#rcr2201-bib-0040){ref-type="ref"}               2013   1     79                                    1                        CLL, PNA             TBB                 WLL                 100

  Bansal [41](#rcr2201-bib-0041){ref-type="ref"}             2013   1     54                                                                                  TBB                 WLL/GM‐CSF          100

  Rojanapremsuk [42](#rcr2201-bib-0042){ref-type="ref"}      2013   1     47                                    1                        PNA, sinusitis       TBB/BAL             Refused treatment   

  Ishii [43](#rcr2201-bib-0043){ref-type="ref"}              2014   31    50                                    31                       MDS                  TBB/OLB                                 

  Fijotek [44](#rcr2201-bib-0044){ref-type="ref"}            2014   17               13                         4                                             BAL/TBB             WLL in 75%          94

  Totals                                                            363              293                        56          3                                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BAL, broncho‐alveolar lavage; CML, chronic myloid leukaemia; CLL, chronic lymphocytic leukaemia; DM, diabetes mellitus; GM‐CSF, granulocyte‐macrophage colony‐stimulating factor; HTN, hypertension; OLB, open lung biopsy; partial LL, partial lung lavage; PAS, periodic acid--Schiff; PJP, pneumocystis jiroveci pneumonia; PNA, pneumonia; SR, spontaneous remission; TB, tuberculosis; TBB, transbronchial biopsy; TMP/SMX, trimethoprim/sulfametoxazole; WLL, whole lung lavage.

WLL had been the standard of therapy since the report by Ramirez [45](#rcr2201-bib-0045){ref-type="ref"} and consequently we managed this reported patient using that intervention. The patient was placed under general anaesthesia, and a double lumen endotracheal tube was inserted; the dependent lung was placed down, a bronchoscope was inserted and after wedging it in a distant airway, we started lavage by instilling normal saline and then suctioning intermittently. Initially we obtained a lavageate that was markedly creamy due to the high lipoproteinaceous content and subsequently it became clear. Approximately 20 L had to be suctioned to get to this point. A week later, we performed WLL of the second lung.

The double lumen endotracheal tube is a key factor because we can \*\*obturate and ventilate one lung and work in the other one. Most of the experts use the "eyeball technique" to estimate how much of lavage is sufficient. The frequency of lavage has to be individualized.

After the advent of GM‐CSF it became a major contributing factor because it was recognized that its deficiency or absence would lead to a significant accumulation of surfactant in the alveolar space. The management of PAP changed forever after this because it became customary to first try GM‐CSF and use WLL only for the therapeutic failure of GM‐CSF. GM‐CSF has been used via inhalational, systemic, or subcutaneous delivery with comparable results.

Finally, it is of utmost importance to analyse and improve the environment of patients. Avoidance of exposure to triggering agents such as silica, mould, or any infective or toxic material is the cornerstone of management of secondary type PAP.
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